Consolidation, IPOs, and Tighter Wallets Will Define Biotech in 02 | GenomeWeb

PALM SPRINGS, Calif., Jan. 29 - The hey day of biotech funding may have passed. But 2002 will see some big mergers, the return of the IPO, and a tighter VC environment, according to Mary Tanner, senior managing director for the pharmaceutical and biotech industries at Bear, Stearns & Co.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.